Prenetics Global Ltd (PRE): Financial results for Q2 2026
Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance, combined with insider purchases, provide a fresh catalyst for price appreciation.
Market read
First‑report earnings with strong growth and insider buying make this a notable micro‑cap event.
What to watch
Potential regulatory scrutiny of health claims and reliance on celebrity partnerships.
Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
Prenetics reported total second quarter revenue of $46.5 million, up approximately 288% year over year, led by IM8 revenue of $45.0 million, up approximately 359% year over year. The Company raised full year 2026 revenue guidance to $220 million to 230 million and introduced full year 2027 revenue guidance of more than $400 million, while reporting its first month of positive consolidated Adjusted Free Cash Flow in July.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total second quarter revenueother | $46.5 million | – | up approximately 288% year over year |
| IM8 revenueother | $45.0 million | – | up approximately 359% year over year |
| IM8 revenue in Julyother | $20.9 million | – | – |
| IM8 annualized revenue run-rateother | approximately $251 million | – | – |
| Consolidated Adjusted Free Cash Flownon-GAAP | positive | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| IM8The brand's sixth consecutive record quarter; IM8 delivered $20.9 million of revenue in July. | $45.0 million | – | up approximately 359% year over year |
full year 2026 and full year 2027 outlook
- Revenuefull year 2026 revenue guidance of $220 million to 230 million; full year 2027 revenue guidance of more than $400 million
What drove it
- IM8 revenue was $45.0 million, up approximately 359% year over year.
- IM8 delivered $20.9 million of revenue in July, with an annualized revenue run-rate of approximately $251 million.
- General Catalyst's Customer Value Fund committed $1 billion of growth financing to IM8.
- IM8 ships to 46 countries and delivers well over 200,000 servings daily.
- Danny Yeung and Brian Rosin acquired $1.0 million of Company ordinary shares in open-market purchases between August 20 and August 25, 2026.
Concerns
- The release does not provide gross profit, gross margin, operating income, net income, EPS, cash balances, debt balances, or the amount of Adjusted Free Cash Flow.
- The Company stated that the impact of the Customer Investment Agreement with GC Customer Value Arranger, LLC is unpredictable and that the arrangement may not function as expected.
- The Company stated that it may require additional capital to grow its business, which may not be available on acceptable terms or at all.
- The Company identified risks relating to sustaining the IM8 business and brand, including negative publicity, customer and content-creator engagement, and meeting customer expectations.
What to watch
- Delivery against full year 2026 revenue guidance of $220 million to 230 million.
- Progress toward full year 2027 revenue guidance of more than $400 million.
- Whether consolidated Adjusted Free Cash Flow remains positive after the first positive month reported in July.
- IM8 revenue progression following July revenue of $20.9 million.
- Deployment and effect of the $1 billion growth-financing commitment to IM8.
Balance sheet and cash flow
- The Company recorded its first month of positive consolidated Adjusted Free Cash Flow in July.
- Adjusted Free Cash Flow, a non-IFRS measure, is defined as net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility.
Analysis
Prenetics reported total second quarter revenue of $46.5 million, up approximately 288% year over year. IM8 supplied $45.0 million of revenue and grew approximately 359% year over year, making it the clear reported revenue driver. The release describes this as IM8's sixth consecutive record quarter.
July extended the reported IM8 growth trajectory, with $20.9 million of revenue and an annualized revenue run-rate of approximately $251 million. The Company also stated that IM8 ships to 46 countries and delivers well over 200,000 servings daily. The filing does not provide other segment revenue, gross profit, operating expenses, earnings, or EPS, so the release does not show the consolidated cost structure or profitability underlying the revenue growth.
Cash-flow commentary improved, with the Company reporting its first month of positive consolidated Adjusted Free Cash Flow in July. This is a non-IFRS measure defined as net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility. No dollar amount for the measure, net cash from operating activities, facility fundings, cash balance, or debt balance was disclosed in this filing.
Management raised full year 2026 revenue guidance to $220 million to 230 million and introduced full year 2027 revenue guidance of more than $400 million. The filing also states that General Catalyst's Customer Value Fund committed $1 billion of growth financing to IM8. Separately, the CEO and CFO acquired $1.0 million of ordinary shares following the second quarter results. The release flags that the impact of the Customer Investment Agreement is unpredictable and that additional capital may be required to grow the business.
Management, verbatim
This is my third open market purchase since November, and the reason has not changed — the business has only gotten stronger. The clearest validation came in July, when General Catalyst's Customer Value Fund committed $1 billion of growth financing to IM8. We turned consolidated Adjusted Free Cash Flow positive in July, raised our FY 2026 revenue guidance, and introduced FY 2027 revenue guidance of more than $400 million, with a strong product pipeline behind it. I would encourage everyone to read our highly detailed shareholder letter and investor presentation we published last week. We are still so early in this journey, and I am backing that view with my own money.
Danny Yeung, Chief Executive Officer of Prenetics
I have spent my career in consumer health and have seen plenty of good brands, but what drew me to IM8 was a set of special characteristics I had not seen combined anywhere else. Three months inside Prenetics, the detail has only confirmed those traits run deeper than I thought. Capital allocation is the core of my job, and I’m applying that same discipline to my own capital and buying in my first available window.
Brian Rosin, Chief Financial Officer
Not in the filing
stated, not guessed- Period-end date
- Revenue for segments other than IM8
- Total revenue prior-year amount
- Total revenue prior-quarter amount
- IM8 revenue prior-year amount
- IM8 revenue prior-quarter amount
- Gross profit and gross margin
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP EPS
- Non-GAAP EPS
- Operating cash flow amount
- Adjusted Free Cash Flow amount
- Cash balance
- Debt balance
- Share repurchases
- Dividends
- Guidance for gross margin, operating expenses, and tax rate
- Prior guidance figures for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Prenetics Global Ltd (NASDAQ: PRE) is a consumer health company behind the AI‑native wellness brand IM8, co‑founded by David Beckham.
Ticker impact
Q2 2026 earnings released with 288% YoY revenue growth, new FY2026 guidance $220‑230M and FY2027 guidance >$400M, plus CEO and CFO each bought ~24k shares worth $1M total.
Potential short‑term price rally as investors digest earnings beat and insider buying.
Revenue surge, positive free cash flow, and significant insider buying are material catalysts for a micro‑cap stock.
Market effects
Highlights rapid growth in consumer health and AI‑driven nutrition, may boost peer valuations.
Positive for US‑listed health‑tech micro‑caps.
Limited to niche health‑tech segment.
Counterpoint
Rapid growth may be unsustainable; valuation could be stretched despite insider buying.
Key entities
- ExecutiveDanny Yeung
CEO of Prenetics, purchased 24,681 shares for $502k.
- ExecutiveBrian Rosin
CFO of Prenetics, purchased 23,100 shares for $498k.
